Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urokinase versus rt-PA by intravenous or intra-arterial thrombolysis for acute ischemic stroke
ChiCTR-TRC-10001745Phase 4Completed
- Sponsor
- Xuanwu Hospital
- Start
- Sep 2004
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of urokinase and tissue-plasminogen activator in ischemic stroke (12 arms), sponsored by Xuanwu Hospital. Primary endpoints: Incidence rate of intracranial hemorrhage within 1 week, 24-hour NIHSS score and 2 more. Started Sep 2004; status: completed.
02
Drugs
urokinasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR-TRC-10001745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001745.